Quantitative magnetic resonance spectroscopic imaging in Parkinson’s disease, progressive supranuclear palsy and multiple system atrophy

Background and purpose:  Magnetic resonance spectroscopy (MRS) allows the measurement of a number of brain tissue metabolites in vivo, including N‐acetylaspartate (NAA), a putative marker of neuronal integrity. Unlike single voxel MRS, magnetic resonance spectroscopic imaging (MRSI) enables quantification of these metabolites simultaneously from multiple anatomically localized voxels. Both single voxel MRS and MRSI allow the absolute quantification of these metabolites and, when combined with tissue segmentation, can give accurate metabolite concentrations even in the presence of partial volume effects from nearby cerebrospinal fluid.

[1]  G K Wenning,et al.  Voxel based morphometry reveals a distinct pattern of frontal atrophy in progressive supranuclear palsy , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[2]  H. Möller,et al.  Localized proton NMR spectroscopy in the striatum of patients with idiopathic Parkinson's disease: a multicenter pilot study. , 1995, Magnetic resonance in medicine.

[3]  I Litvan,et al.  Consensus statement on the diagnosis of multiple system atrophy , 1998, Journal of the Neurological Sciences.

[4]  D. Brooks,et al.  A Proton Magnetic Resonance Spectroscopy Study of the Striatum and Cerebral Cortex in Parkinson's Disease , 1999, Metabolic Brain Disease.

[5]  T. Mareci,et al.  Selective fourier transform localization , 1987, Magnetic resonance in medicine.

[6]  S. Provencher.  Estimation of metabolite concentrations from localized in vivo proton NMR spectra , 1993, Magnetic resonance in medicine.

[7]  C. Clarke,et al.  Basal ganglia metabolite concentrations in idiopathic Parkinson's disease and multiple system atrophy measured by proton magnetic resonance spectroscopy , 2000, European journal of neurology.

[8]  G J Barker,et al.  Quantitative analysis of short echo time 1H‐MRSI of cerebral gray and white matter , 2000, Magnetic resonance in medicine.

[9]  H. Bruhn,et al.  Localized high‐resolution proton NMR spectroscopy using stimulated echoes: Initial applications to human brain in vivo , 1989, Magnetic resonance in medicine.

[10]  C. Clarke,et al.  Systematic review of proton magnetic resonance spectroscopy of the striatum in parkinsonian syndromes , 2001, European journal of neurology.

[11]  M. Hallett,et al.  Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration. , 1997, Brain : a journal of neurology.

[12]  A. Horsman,et al.  Unchanged basal ganglia N‐acetylaspartate and glutamate in idiopathic Parkinson's disease measured by proton magnetic resonance spectroscopy , 1997, Movement disorders : official journal of the Movement Disorder Society.

[13]  B D Ross,et al.  Quantitative proton-decoupled 31P MRS and 1H MRS in the evaluation of Huntington's and Parkinson's diseases , 1998, Neurology.

[14]  M. T. Pellecchia,et al.  Diffusion‐weighted imaging in multiple system atrophy: A comparison between clinical subtypes , 2009, Movement disorders : official journal of the Movement Disorder Society.

[15]  N. Schuff,et al.  Quantitative 1H magnetic resonance spectroscopy and MRI of Parkinson's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.

[16]  David H. Miller,et al.  Proton magnetic resonance spectroscopy in steele‐richardson‐olszewski syndrome , 1997, Movement disorders : official journal of the Movement Disorder Society.

[17]  Christian Kremser,et al.  Trace of diffusion tensor differentiates the Parkinson variant of multiple system atrophy and Parkinson's disease , 2004, NeuroImage.

[18]  C Kremser,et al.  Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy , 2003, Neurology.

[19]  Nick C. Fox,et al.  Voxel-based morphometry detects patterns of atrophy that help differentiate progressive supranuclear palsy and Parkinson's disease , 2004, NeuroImage.

[20]  I. McKeith,et al.  SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders , 2003, Movement disorders : official journal of the Movement Disorder Society.

[21]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[22]  Karl J. Friston,et al.  Unified segmentation , 2005, NeuroImage.

[23]  M. Weiner,et al.  Proton MR spectroscopic imaging of the striatum in Parkinson's disease. , 1997, Magnetic resonance imaging.

[24]  D. Dubowitz,et al.  In vivo magnetic resonance spectroscopy of human fetal neural transplants , 1999, NMR in biomedicine.

[25]  S. Provencher.  Automatic quantitation of localized in vivo 1H spectra with LCModel , 2001, NMR in biomedicine.

[26]  Andrew J Lees,et al.  Diffusion‐weighted magnetic resonance imaging differentiates Parkinsonian variant of multiple‐system atrophy from progressive supranuclear palsy , 2007, Movement disorders : official journal of the Movement Disorder Society.

[27]  Tae-Suk Suh,et al.  Metabolic Alterations in Parkinson's Disease after Thalamotomy, as Revealed by 1H MR Spectroscopy , 2002, Korean journal of radiology.

[28]  Francesco Fera,et al.  Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson's disease and progressive supranuclear palsy. , 2006, Brain : a journal of neurology.

[29]  P. Bottomley.  Spatial Localization in NMR Spectroscopy in Vivo , 1987, Annals of the New York Academy of Sciences.

[30]  K. Abe,et al.  Proton magnetic resonance spectroscopy of patients with parkinsonism , 2000, Brain Research Bulletin.

[31]  H. Möller,et al.  Localized proton NMR spectroscopy in the striatum of patients with idiopathic parkinson's disease: a multicenter pilot study , 1995 .

[32]  C. Büchel,et al.  Voxel‐based morphometry detects cortical atrophy in the Parkinson variant of multiple system atrophy , 2003, Movement disorders : official journal of the Movement Disorder Society.

[33]  M. Tosetti,et al.  Proton magnetic resonance spectroscopy (1H-MRS) of motor cortex and basal ganglia in de novo Parkinson's disease patients , 2001, Neurological Sciences.

[34]  A. Simmons,et al.  Changes in putamen N-acetylaspartate and choline ratios in untreated and levodopa-treated Parkinson's disease: A proton magnetic resonance spectroscopy study , 1997, Neurology.

[35]  A. Lees,et al.  Striatonigral degeneration. A clinicopathological study. , 1990, Brain : a journal of neurology.

[36]  Michael Schocke,et al.  Progression of brain atrophy in multiple system atrophy , 2007, Journal of Neurology.

[37]  H. Watanabe,et al.  Multiple regional 1H-MR spectroscopy in multiple system atrophy: NAA/Cr reduction in pontine base as a valuable diagnostic marker. , 2004, Journal of neurology, neurosurgery, and psychiatry.

[38]  D Matthaei,et al.  1H NMR chemical shift selective (CHESS) imaging. , 1985, Physics in medicine and biology.

[39]  S Mierisová,et al.  MR spectroscopy quantitation: a review of frequency domain methods , 2001, NMR in biomedicine.

[40]  C. Marsden,et al.  Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy , 1995, Annals of neurology.

[41]  P. Lamberti,et al.  Usefulness of proton magnetic resonance spectroscopy in differentiating parkinsonian syndromes , 1999, The Italian Journal of Neurological Sciences.

[42]  Proton magnetic resonance spectroscopy of the striatum in Parkinson's disease patients with motor response fluctuations. , 1996, Parkinsonism & related disorders.

[43]  Jan Aasly,et al.  Applications of neural network analyses to in vivo 1H magnetic resonance spectroscopy of Parkinson disease patients , 2002, Journal of magnetic resonance imaging : JMRI.

[44]  A. Mackay,et al.  Proton T1 relaxation times of cerebral metabolites differ within and between regions of normal human brain , 2003, NMR in biomedicine.